var data={"title":"Asfotase alfa: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Asfotase alfa: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/790810?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=asfotase-alfa-drug-information\" class=\"drug drug_general\">see &quot;Asfotase alfa: Drug information&quot;</a> and <a href=\"topic.htm?path=asfotase-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Asfotase alfa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653212\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Strensiq</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49308231\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Strensiq</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46149897\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46889264\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Round patient weight to the nearest kg when determining dose. Do not administer the 80 mg/0.8 mL concentration vial to neonates; systemic exposure is less than what is achieved with lower concentration vials. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perinatal/infantile-onset hypophosphatasia (HPP):</b> SubQ: 6 mg/kg/week administered as either 2 mg/kg/dose 3 times weekly or 1 mg/kg/dose 6 times weekly; may increase dose up to 9 mg/kg/week administered as 3 mg/kg/dose 3 times weekly; in clinical trials, dose increases were considered after at least 4 weeks of therapy (Whyte 2012; Whyte 2016); maximum total weekly dose: 9 mg/kg/week. <b>Note: </b>In trials, lack of efficacy (clinical response) may be defined as no improvement in respiratory status, growth, or radiographic findings. Injection site reactions may limit the tolerability of the-6 times-per-week regimen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46149901\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=asfotase-alfa-drug-information\" class=\"drug drug_general\">see &quot;Asfotase alfa: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Round patient weight to the nearest kg when determining dose. Do not administer the 80 mg/0.8 mL concentration vial to pediatric patients weighing &lt;40 kg; exposure is less than what is achieved with lower concentration vials. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perinatal/infantile-onset hypophosphatasia (HPP):</b> Infants, Children, and Adolescents: SubQ: 6 mg/kg/week administered as either 2 mg/kg/dose 3 times weekly or 1 mg/kg/dose 6 times weekly; may increase dose up to 9 mg/kg/week administered as 3 mg/kg/dose 3 times weekly; in clinical trials, dose increases were considered after at least 4 weeks of therapy (Whyte 2012; Whyte 2016); maximum total weekly dose: 9 mg/kg/week. <b>Note:</b> Lack of clinical response may be defined as no improvement in respiratory status, growth, or radiographic findings. Injection site reactions may limit the tolerability of the 6-times-per-week regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile-onset hypophosphatasia (HPP):</b> Children and Adolescents: SubQ: 6 mg/kg/week administered as either 2 mg/kg/dose 3 times weekly or 1 mg/kg/dose 6 times weekly. Injection site reactions may limit the tolerability of the 6-times-per-week regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Juvenile-onset hypophosphatasia (HPP):</b> SubQ: 6 mg/kg/week administered as either 2 mg/kg/dose 3 times weekly or 1 mg/kg/dose 6 times weekly. <b>Note:</b> Round patient weight to the nearest kg when determining dose.  Injection-site reactions may limit the tolerability of the 6-times-per-week regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653213\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strensiq: 18 mg/0.45 mL (0.45 mL); 28 mg/0.7 mL (0.7 mL); 40 mg/mL (1 mL); 80 mg/0.8 mL (0.8 mL) [contains mouse (murine) and/or hamster protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653211\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46149902\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: For subcutaneous administration only in the abdominal area, thigh, or deltoid. Administer within 1 hour upon removal from refrigerator. Rotate the injection sites to reduce the risk of lipodystrophy. Do not administer injections in areas that are reddened, inflamed, or swollen. Solution is clear, slightly opalescent or opalescent, colorless to slightly yellow; few small translucent or white particles may be present; discard vial(s) not consistent with this appearance. Administer with 1 mL syringe with <sup>1</sup>/<sub>2</sub>-inch needle (25 to 29 gauge). For doses &gt;1 mL, split the volume equally between 2 syringes, and administer 2 injections using separate injection sites. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In pediatric patients &lt;40 kg, do not use the 80 mg/0.8 mL vial; systemic exposure of asfotase alfa achieved with this higher concentration (80 mg/0.8 mL) is lower than that achieved with the other vial strengths which have a lower concentration. A lower exposure may not be adequate for this subgroup of patients. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45642721\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in original carton and protect from light. Once removed from refrigerator, administer within 1 hour. Do not freeze or shake. Discard any unused product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46149898\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Treatment of perinatal/infantile- and juvenile-onset hypophosphatasia (HPP) (FDA approved in all ages) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45591541\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Ectopic calcification (includes calcification of the cornea, conjunctiva, and kidneys; juvenile-onset HPP; perinatal/infantile-onset HPP), lipodystrophy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunogenicity (positive for antidrug antibodies; neutralizing; presence of antidrug antibodies resulted in reduced systemic exposure of asfotase alfa) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Atrophy at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), bruising at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), erythema at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), hypertrophy at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), induration at injection site, injection site reaction (including rash, nodule, papule, inflammation, hemorrhage, hematoma, calcification, mass, scar, cellulitis, or not otherwise defined), itching at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), pain at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), skin discoloration at injection site (including macules: More common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), swelling at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP), tenderness at injection site (more common in juvenile-onset HPP; also in perinatal/infantile-onset HPP)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Chronic active hepatitis, hypocalcemia, nephrolithiasis, pyridoxine deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45497570\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to asfotase alfa or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45642719\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The presence of antibodies has been reported in 78% of treated patients in clinical trials. Approximately 45% of these patients showed the presence of neutralizing antibodies. Formation of anti-drug antibody results in a reduced systemic exposure of asfotase alfa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ectopic calcifications: Ectopic calcification of the eye, including the cornea and conjunctiva, and the kidneys (nephrocalcinosis) have been reported; there is insufficient information to determine if these events were consistent with the disease (patients with hypophosphatasia are at increased risk for developing ectopic calcifications) or due to asfotase alfa. No visual changes or changes in renal function were reported resulting from the occurrence of ectopic calcifications. Eye exams and renal ultrasounds are recommended at baseline and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported; symptoms consistent with anaphylaxis, including difficulty breathing, choking sensation, nausea, periorbital edema, and dizziness, have been reported. Reactions may occur within minutes after administration or in patients on treatment for &gt;1 year. Other hypersensitivity reactions (eg, vomiting, fever, headache, flushing, irritability, chills, skin erythema, rash, pruritus, oral hypoesthesia) have also been reported. If a severe hypersensitivity reaction occurs, discontinue treatment and initiate appropriate medical treatment. If the decision is made to re-administer, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipodystrophy: Localized lipodystrophy, including lipoatrophy and lipohypertrophy, has been reported at injection sites after several months. Ensure proper injection technique and rotate injection sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated alkaline phosphatase (ALP): High serum ALP levels are expected and reflect circulating asfotase alfa; serum ALP measurements should not be used to make clinical decisions during asfotase alfa treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46889263\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Craniosynostosis associated with increased intracranial pressure in some cases and worsening of preexisting craniosynostosis has been reported in clinical trials in patients &lt;5 years of age; causality with asfotase alfa has not been established due to insufficient data; craniosynostosis is frequently reported (61.3%) in patient with hypophosphatasia as manifestation of the condition. Monitor (eg, fundoscopy) patients &lt;5 years of age periodically (Stensiq prescribing information [European Medicines Agency] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525226\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525223\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109307&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45642684\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46149903\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reaction; signs and symptoms of ophthalmic and renal ectopic calcifications and for changes in vision or renal function; periodic evaluations for craniosynostosis (fundoscopy) in patients &lt;5 years of age </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45642722\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Asfotase alfa is a human recombinant tissue-nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein with enzymatic activity that promotes bone mineralization in patients with hypophosphatasia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45642724\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Reduction in plasma tissue-nonspecific alkaline phosphatase (TNSALP): After 6 to 12 weeks of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Age range: 1 day to 66 years:  Subcutaneous: 60.2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~5 days (based on data from 38 patients, ages undefined); in 60 patients aged 1 day to 66 years (n=45 pediatric patients):  ~2.3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak serum concentration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &le;5 years: ~15 hours (range: 0 to 32.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt; 5 to 12 years:  ~ 21 hours (range: 12 to 32.2 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45762888\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Strensiq Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg/0.45ml (0.45 mL): $1,544.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">28 mg/0.7 mL (0.7 mL): $2,402.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (1 mL): $3,432.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/0.8 mL (0.8 mL): $6,864.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45524837\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Strensiq (AT, CZ, DE, DK, EE, FR, HR, IE, JP, LT, LV, NO, PL, PT, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Strensiq (asfotase alfa) [prescribing information]. Cheshire, CT: Alexion Pharmaceuticals Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strensiq European (asfotase alfa) [prescribing information]. Dublin, Ireland: Alexion Pharma International Trading; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. <i>N Engl J Med</i>. 2012; 366(10):904-913.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. <i>J Clin Endocrinol Metab</i>. 2016;101(1):334-342.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109307 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45653212\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49308231\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F46149897\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F46889264\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F46149901\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45653213\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F45653211\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46149902\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45642721\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46149898\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45591541\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45497570\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45642719\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46889263\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45525226\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45525223\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45642684\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46149903\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45642722\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45642724\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45762888\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45524837\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/109307|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=asfotase-alfa-drug-information\" class=\"drug drug_general\">Asfotase alfa: Drug information</a></li><li><a href=\"topic.htm?path=asfotase-alfa-patient-drug-information\" class=\"drug drug_patient\">Asfotase alfa: Patient drug information</a></li></ul></div></div>","javascript":null}